VTVT revenueQ3 2026$0
- FY YoY
- -100.0%
VTVT revenue was $0 in fiscal Q3 2026 (ended Sep 30, 2026), compared with $0 a year earlier. For the full fiscal 2025 it was $0, down 100.0% from fiscal 2024.
vTv Therapeutics Inc. (VTVT) financials
For the twelve months ended Sep 30, 2026, vTv Therapeutics Inc. reported $36.84M of revenue and -$7.68M of net income.
- Revenue, TTM
- $36.84M
- Revenue growth, YoY
- +216600.0%
- Net income, TTM
- -$7.68M
- Net margin
- -20.8%
- Cash
- $77.16M
- P/S
- 2.29
- Market cap
- $84.2M
FY2016FY2025
FY2016FY2025
FY2016FY2024
VTVT revenue and earnings growth
VTVT net incomeQ3 2026-$11.62M
VTVT net income was -$11.62M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$8.70M a year earlier. For the full fiscal 2025 it was -$26.97M, compared with -$18.46M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1.02M | $0 | $2.02M | $4.00M | $6.41M | $2.76M | $12.43M | $291.0K | $634.0K |
| Research and development | $17.86M | $11.55M | $13.60M | $12.36M | $13.32M | $11.02M | $15.12M | $23.04M | $39.64M | $44.95M |
| Selling, general and admin | $14.95M | $13.65M | $11.91M | $12.20M | $12.34M | $7.25M | $8.54M | $9.22M | $11.33M | $9.91M |
| Operating income | -$32.81M | -$24.18M | -$25.50M | -$22.54M | -$21.66M | -$11.85M | -$20.89M | -$19.82M | -$50.68M | -$55.02M |
| Interest expense | - | $0 | $13.0K | $15.0K | $12.0K | $692.0K | $1.83M | $3.29M | $3.09M | $398.0K |
| Pre-tax income | -$31.08M | -$22.61M | -$25.97M | -$24.87M | -$17.62M | -$12.80M | -$21.84M | -$23.64M | -$53.85M | -$55.35M |
| Income tax | $0 | $100.0K | $0 | $200.0K | $115.0K | $0 | $100.0K | $200.0K | $800.0K | $0 |
| Net income | -$26.97M | -$18.46M | -$20.25M | -$19.16M | -$12.99M | -$8.50M | -$13.04M | -$7.91M | -$16.14M | -$16.35M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $88.93M | $36.75M | $9.45M | $12.13M | $13.41M | $5.75M | $4.28M | $4.18M | $14.42M | $51.51M |
| Receivables | - | $62.0K | $102.0K | $173.0K | $57.0K | $158.0K | $5.0K | $0 | $8.00M | $0 |
| Current assets | $89.89M | $38.11M | $10.66M | $27.09M | $15.62M | $7.21M | $2.84M | $3.47M | $20.36M | $52.12M |
| Total assets | $89.90M | $38.27M | $11.02M | $33.24M | $25.47M | $14.79M | $9.27M | $8.56M | $27.92M | $54.49M |
| Current liabilities | $6.64M | $5.20M | $10.62M | $7.71M | $8.50M | $6.39M | $13.38M | $18.84M | $26.93M | $11.43M |
| Short-term debt | - | - | - | - | $256.0K | $84.0K | $144.0K | $216.0K | - | - |
| Total debt | - | $0 | $191.0K | $224.0K | $256.0K | $84.0K | $6.17M | $15.71M | $19.59M | $11.06M |
| Total liabilities | $25.46M | $23.96M | $29.57M | $27.40M | $10.25M | $11.00M | $18.11M | $28.93M | $47.52M | $22.93M |
| Shareholders' equity | $64.44M | $14.30M | -$24.68M | -$10.74M | -$9.74M | -$80.10M | -$49.02M | -$82.85M | -$151.05M | -$90.94M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$25.25M | -$25.31M | -$19.08M | -$16.02M | -$19.31M | -$18.00M | -$23.02M | -$26.86M | -$44.56M | -$48.21M |
| Capital expenditures | - | $0 | $0 | $21.0K | $0 | $0 | $70.0K | $5.0K | $57.0K | $87.0K |
| Free cash flow | - | -$25.31M | -$19.08M | -$16.04M | -$19.31M | -$18.00M | -$23.09M | -$26.86M | -$44.62M | -$48.30M |
| Investing cash flow | $0 | $0 | $4.40M | -$21.0K | $0 | $0 | $242.0K | $7.0K | -$25.0K | -$83.0K |
| Financing cash flow | $77.44M | $52.61M | $12.00M | $14.75M | $26.98M | $19.47M | $22.87M | $16.61M | $7.50M | $11.79M |
| Stock-based compensation | $3.77M | $2.76M | $1.58M | $1.27M | $2.36M | $1.01M | $1.52M | $2.68M | $3.65M | $2.64M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -100.0% | - | -100.0% | -49.6% | -37.6% | 132.1% | -77.8% | 4172.9% | -54.1% | 22.2% |
| Operating margin | - | -2377.6% | - | -1116.9% | -540.9% | -184.8% | -755.9% | -159.4% | -17416.5% | -8678.2% |
| Net margin | - | -1815.3% | - | -949.7% | -324.3% | -132.5% | -471.9% | -63.6% | -5547.8% | -2579.2% |
| Free cash flow margin | - | -2488.4% | - | -795.0% | -482.1% | -280.6% | -835.3% | -216.0% | -15332.3% | -7617.7% |
| Return on equity | -41.9% | -129.1% | - | - | - | - | - | - | - | - |
| Return on assets | -30.0% | -48.2% | -183.8% | -57.7% | -51.0% | -57.5% | -140.8% | -92.4% | -57.8% | -30.0% |
| Current ratio | 13.54 | 7.34 | 1.00 | 3.52 | 1.84 | 1.13 | 0.21 | 0.18 | 0.76 | 4.56 |
| Debt to equity | - | 0.00 | - | - | - | - | - | - | - | - |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $36.84M | $0 | $0 | $0 | $0 | $17.0K | $0 | $0 | $1.00M | $0 |
| Research and development | $7.53M | $8.77M | $8.98M | $3.91M | $7.02M | $4.10M | $2.83M | $2.23M | $3.22M | $3.44M | $2.65M | $2.14M |
| Selling, general and admin | $4.89M | $5.16M | $4.60M | $3.98M | $3.68M | $3.62M | $3.67M | $2.67M | $3.28M | $3.72M | $3.98M | $2.57M |
| Operating income | -$12.43M | -$13.93M | $23.26M | -$7.88M | -$10.70M | -$7.72M | -$6.50M | -$4.89M | -$6.51M | -$7.16M | -$5.63M | -$4.71M |
| Interest expense | - | - | - | - | - | - | - | - | - | - | - | $7.0K |
| Pre-tax income | -$11.62M | -$13.05M | $24.13M | -$7.14M | -$10.35M | -$7.38M | -$6.22M | -$4.44M | -$5.84M | -$6.41M | -$5.92M | -$4.44M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $100.0K | $0 |
| Net income | -$11.62M | -$13.05M | $24.13M | -$7.14M | -$8.70M | -$6.05M | -$5.09M | -$3.63M | -$4.78M | -$5.18M | -$4.87M | -$3.48M |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $77.16M | $86.64M | $98.09M | $88.93M | $98.50M | $25.92M | $31.06M | $36.75M | $41.57M | $45.53M | $52.26M | $9.45M |
| Receivables | - | - | - | - | - | - | - | $62.0K | $242.0K | $306.0K | $981.0K | $102.0K |
| Current assets | $78.60M | $87.59M | $98.81M | $89.89M | $99.46M | $26.37M | $31.92M | $38.11M | $42.96M | $46.20M | $53.87M | $10.66M |
| Total assets | $78.61M | $87.59M | $98.81M | $89.90M | $99.49M | $26.45M | $32.03M | $38.27M | $43.16M | $46.46M | $54.18M | $11.02M |
| Current liabilities | $7.02M | $7.02M | $6.88M | $6.64M | $10.16M | $5.29M | $4.32M | $5.20M | $6.42M | $6.99M | $8.92M | $10.62M |
| Total debt | - | - | - | - | - | - | - | $0 | - | - | - | $191.0K |
| Total liabilities | $8.92M | $8.96M | $8.85M | $25.46M | $28.95M | $24.04M | $23.13M | $23.96M | $25.25M | $26.02M | $28.20M | $29.57M |
| Shareholders' equity | $69.69M | $78.63M | $89.96M | $64.44M | $70.54M | $2.40M | $8.90M | $14.30M | $17.91M | $20.44M | $25.99M | -$24.68M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.19M | -$11.44M | $9.15M | -$9.25M | -$5.22M | -$5.09M | -$5.69M | -$4.83M | -$6.42M | -$6.73M | -$7.33M | -$2.91M |
| Capital expenditures | - | - | - | - | - | - | - | - | - | - | - | $0 |
| Free cash flow | - | - | - | - | - | - | - | - | - | - | - | -$2.91M |
| Investing cash flow | - | - | - | - | - | - | - | - | - | - | - | $4.40M |
| Financing cash flow | $709.0K | - | - | -$321.0K | $77.80M | -$42.0K | $0 | $0 | $2.46M | $0 | $50.14M | -$282.0K |
| Stock-based compensation | $1.97M | $1.73M | $1.39M | $1.02M | $1.01M | $930.0K | $813.0K | $825.0K | $853.0K | $859.0K | $220.0K | $403.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | -100.0% | - | - | -100.0% | - | - | - | - | -100.0% |
| Operating margin | - | - | 63.1% | - | - | - | - | -28776.5% | - | - | -562.7% | - |
| Net margin | - | - | 65.5% | - | - | - | - | -21376.5% | - | - | -486.5% | - |
| Current ratio | 11.19 | 12.48 | 14.36 | 13.54 | 9.79 | 4.98 | 7.39 | 7.34 | 6.69 | 6.61 | 6.04 | 1.00 |
| Debt to equity | - | - | - | - | - | - | - | 0.00 | - | - | - | - |
Source: XBRL data vTv Therapeutics Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
VTVT peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| VTVT | $36.84M | +216600.0% | -$7.68M | -20.8% | $84.2M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
VTVT FAQ
6 questionsWhat is VTVT revenue?
vTv Therapeutics Inc. (VTVT) reported $36.84M of revenue for the twelve months ended Sep 30, 2026. That is up 216600.0% from the year before. Revenue for fiscal 2025 was $0.Is VTVT profitable?
No. vTv Therapeutics Inc. reported a net loss of $7.68M for the twelve months ended Sep 30, 2026.How much cash and debt does VTVT have?
vTv Therapeutics Inc. reported $77.16M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is VTVT revenue growing?
vTv Therapeutics Inc.'s revenue changed -100.0% in fiscal 2025, to $0.When did VTVT last report financial results?
The latest statements here come from vTv Therapeutics Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.Where does this VTVT financial data come from?
Quantisnow builds these statements from the structured XBRL data vTv Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.